No Data
Ascendis Pharma Is Maintained at Outperform by RBC Capital
Ascendis Pharma Is Maintained at Outperform by Wedbush
Ascendis Pharma Is Maintained at Outperform by Evercore ISI Group
Ascendis Pharma Analyst Ratings
Express News | Ascendis Pharma A/S : Leerink Partners Raises Target Price to $200 From $190
RBC Raises Price Target on Ascendis Pharma to $210 From $205, Keeps Outperform, Speculative Risk